Skip to main content

Person Putting a Drop on Test Tube Free Stock Photo

Emergent BioSolutions revealed this week plans to expand its viral vector and gene therapy capabilities.

The company announced it will invest $75 million in its Canton, Mass., facility, which is focused on the contract development and manufacturing (CDMO) of drug substances for live viral vaccines, including the company’s smallpox vaccine

 

{iframe}https://homelandprepnews.com/stories/51062-emergent-biosolutions-invests-75m-in-viral-vector-gene-therapy-capabilities/?amp{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.